Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient and tumor characteristics by study cohort

From: Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Characteristic Total patients (n = 27) PIK3CA/AKT cohort (n = 18) PTEN cohort (n = 9)
Age
 Mean (range) 52 (30–73) 54 (33–73) 48 (30–68)
Race
 Caucasian 24 (89%) 16 (89%) 8 (89%)
 African-American 3 (11%) 2 (11%) 1 (11%)
ECOG performance status
 0 19 (70%) 13 (72%) 6 (67%)
 1 8 (30%) 5 (28%) 3 (33%)
Subtype
 HR+ 15 (56%) 12 (67%) 3 (33%)
 TNBC 9 (33%) 4 (22%) 5 (56%)
 HER+ 3 (11%) 2 (11%) 1 (11%)
Molecular subtype
PIK3CA mutant 13 (48%) 13 (72%)
AKT1 mutant 4 (15%) 4 (22%)
PIK3CA mutant and PTEN loss 1 (4%) 1 (6%)
 PTEN loss 9 (33%) 9 (100%)
Number of prior therapies
 2 2 (7%) 1 (5%) 1 (11%)
 3 3 (11%) 1 (5%) 2 (22%)
 ≥ 4 22 (82%) 16 (90%) 6 (67%)